white paper

A Double-Masked, Randomized, Sham-Controlled Single-Center Study With Photobiomodulation for the Treatment of Dry Age-Related Macular Degeneration

/in /by

Abstract

Photobiomodulation treatment in a randomized, sham-controlled, single-center, double-masked study conducted in 46 eyes of patients with dry age-related macular degeneration significantly improved functional (visual acuity and contrast sensitivity) and anatomical (drusen volume and central drusen thickness) outcomes. Patient improvements were reported in the VFQ-25 assessing activities of daily living.

Read More» | Download PDF»

white paper

Longer wavelengths in sunlight pass through the human body and have a systemic impact which improves vision

/in /by

Abstract

Long wavelength red light that can extend beyond the human visual range penetrates deeply through biological tissue. Exposure to these longer wavelengths improves mitochondrial function and ATP production. This can translate to improved physiological performance, particularly in the CNS, including the visual system. Light driven metabolic improvements to regional exposure can impact systemically. Here we show that infrared wavelengths from sunlight can be measured after they pass through the human thorax. We then select a prominent transmitted solar wavelength range (830–860 nm) and deliver this to the thorax of subjects in the lab in controlled 15 min exposures with and without ocular involvement. Clothing reduced wavelength intensity but was not a barrier. These exposures were associated with significantly improved visual function when measured 24 h later even in subjects in which light was blocked from the eyes. Our data show that longer wavelengths
of sunlight penetrate through the human body and, consistent with animal studies, have the ability to improve function. While infrared light has been used on targeted tissues, its ability to improve distal tissues in humans has not been explored. This study also highlights the potentially important therapeutic value of sunlight whose longer wavelengths can reach key organs even through clothing and likely promote mitochondrial function counteracting the decline with age and disease.

Read More» | Download PDF»

 

Photobiomodulation therapy for congenital color vision deficiency: results of a preliminary randomized clinical trial

/in /by

Abstract

Purpose: This study presents a novel randomized controlled trial investigating photobiomodulation (PBM) therapy as an intervention method for color vision deficiency (CVD).

Methods: A total of 74 participants with CVD were assigned to either the PBM group or the control group. In the PBM group, participants wore virtual reality (VR) goggles twice daily, with a 12-h interval, over a four-week period. The VR video consisted of alternating red and green images, each presented for 5 s, totaling 6 min and 20 s. No treatment was administered to the control group. Color vision improvement was assessed using Yu’s, Ishihara’s pseudoachromatic plates, Color Blindness Check (CBC), and FM-100 Hue total error score (TES).

Results: After 4 weeks, in terms of Yu’s and Ishihara’s Plates, the patients in PBM group could identify increasing pieces (before: 1.6 ± 1.6, 2.3 ± 2.2; 4 weeks: 6.5 ± 4.4, 5.4 ± 2.9), while in control group, the number was before: 2.6 ± 3.4, 2.6 ± 2.5; 4 weeks: 3.3 ± 3.6, 2.9 ± 2.2. As for CBC scores, the patients in PBM also showed improved high scores (before: 2353.3 ± 700.0; 4 weeks: 2693.6 ± 642.5). Moreover, PBM treatment resulted in a significant reduction of FM-100 scores (before: 298.0 ± 211.3; 4 weeks: 202.1 ± 114.4).

Conclusion: These findings suggest that PBM therapy holds promise as a potential treatment option for individuals with CVD.

Read More» | Download PDF»

 

white paper

LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System

/in /by

Abstract

Purpose: The LIGHTSITE III study evaluated multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) age-related macular degeneration (AMD) using the LumiThera Valeda Light Delivery System.

Methods: LIGHTSITE III is a randomized, controlled trial to assess the safety and effectiveness of PBM in dry AMD. Subjects were given multiwavelength PBM (590, 660, and 850 nm) or Sham treatment delivered in a series of nine sessions over 3 to 5 weeks every four months over 24 months. Subjects were assessed for efficacy and safety outcomes. Data from the 13-month analysis are presented in this report.

Results: A total of 100 subjects (148 eyes) with dry AMD were randomized. LIGHTSITE III met the primary efficacy best-corrected visual acuity endpoint with a significant difference between PBM (n = 91 eyes) and Sham (n = 54 eyes) groups (Between group difference: 2.4 letters (SE 1.15), CI: -4.7 to -0.1, P = 0.02) (PBM alone: 5.4 letters (SE 0.96), CI: 3.5 to 7.3, P < 0.0001; Sham alone: 3.0 letters (SE 1.13), CI: 0.7-5.2, P < 0.0001). The PBM group showed a significant decrease in new onset geographic atrophy ( P = 0.024, Fisher exact test, odds ratio 9.4). A favorable safety profile was observed.

Conclusion: LIGHTSITE III provides a prospective, randomized, controlled trial showing improved clinical and anatomical outcomes in intermediate dry AMD following PBM therapy.

Read More on nih.gov or download the PDF.

white paper

Light Therapy Might Help Ease ‘Dry’ Form of Macular Degeneration

/in /by

Abstract

Light therapy, a painless, noninvasive treatment, could significantly lower your risk of vision loss from dry age-related macular degeneration (AMD), according to a study presented at AAO 2024, the annual meeting of the American Academy of Ophthalmology (AAO).1

Read more on mercola.com or download the PDF»

 

white paper

Safety, Tolerability, and Short-Term Efficacy of Low-Level Light Therapy for Dry Age-Related Macular Degeneration

/in /by

Abstract

Photobiomodulation (PBM) has become a promising approach for slowing the progression of early and intermediate dry age-related macular degeneration (dAMD) to advanced AMD. This technique uses light to penetrate tissues and activate molecules that influence biochemical reactions and cellular metabolism. This preliminary analysis is aimed at assessing the safety, tolerability, and short-term effectiveness of the EYE-LIGHT®PBM treatment device in patients with dAMD.

Read more on nih.gov or download the PDF»

 

white paper

13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System

/in /by

Abstract

Purpose: The LIGHTSITE III study evaluated multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) age-related macular degeneration (AMD) using the LumiThera Valeda Light Delivery System.

Methods: LIGHTSITE III is a randomized, controlled trial to assess the safety and effectiveness of PBM in dry AMD. Subjects were given multiwavelength PBM (590, 660, and 850 nm) or Sham treatment delivered in a series of nine sessions over 3 to 5 weeks every four months over 24 months. Subjects were assessed for efficacy and safety outcomes. Data from the 13-month analysis are presented in this report.

Results: A total of 100 subjects (148 eyes) with dry AMD were randomized. LIGHTSITE III met the primary efficacy best-corrected visual acuity endpoint with a significant difference between PBM (n = 91 eyes) and Sham (n = 54 eyes) groups (Between group difference: 2.4 letters (SE 1.15), CI: −4.7 to −0.1, P = 0.02) (PBM alone: 5.4 letters (SE 0.96), CI: 3.5 to 7.3, P < 0.0001; Sham alone: 3.0 letters (SE 1.13), CI: 0.7–5.2, P < 0.0001). The PBM group showed a significant decrease in new onset geographic atrophy (P = 0.024, Fisher exact test, odds ratio 9.4). A favorable safety profile was observed.

Conclusion: LIGHTSITE III provides a prospective, randomized, controlled trial showing improved clinical and anatomical outcomes in intermediate dry AMD following PBM therapy.

Read more on lww.com or download the PDF»

 

white paper

FDA Authorizes Light Therapy for Dry AMD

/in /by

Abstract

Imagine a special light that could protect vision in people with dry age-related macular degeneration (dry AMD) without eye injections. That’s what a new treatment aims to do.

Dry AMD affects mostly adults over 55, and it’s a leading cause of vision loss. Right now, only specific types of dry AMD can be treated — and the treatment involves eye injections that may slow the disease without improving vision. Some patients with dry AMD may also benefit from special vitamins.

The new light therapy — called photobiomodulation — could be a big breakthrough. It’s the first non-invasive treatment authorized by the FDA for use in treating dry AMD, which means no needles are needed.

Read more on aao.org or download the PDF»